The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Advances in Connective Tissue Disease-Associated Interstitial Lung Disease

Advances in Connective Tissue Disease-Associated Interstitial Lung Disease

December 1, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence 2021—The past year has been an exciting time for researchers and clinicians focused on the topic of connective tissue disease-associated interstitial lung disease (CTD-ILD), with advances in our understanding of these disorders and newly approved medications for their treatment. At the ACR Convergence 2021 annual Review Course, Kristin Highland, MD, MSCR, director of the Rheumatic Lung Disease Program at the Cleveland Clinic, provided an exceptional overview of this topic and future developments to expect in the field.

You Might Also Like
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • Tackle Tricky Lung Complications in Connective Tissue Disease
Also By This Author
  • Never Too Late: Late-Breaking Abstracts Create Excitement

Significant Source of Morbidity & Mortality

Dr. Highland

Dr. Highland began by noting that CTD-ILD can be prevalent in certain rheumatic diseases and can represent a significant source of morbidity and mortality. In scleroderma, autopsy studies have demonstrated the presence of ILD in 75–95% of patients and, although scleroderma renal crisis was the leading cause of death in patients in the early 1970s, pulmonary fibrosis became the leading cause of mortality in patients with scleroderma by the early 2000s.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In patients with rheumatoid arthritis, the prevalence of ILD is estimated to be 5–58%, with a 7.7% lifetime risk of developing this condition, which can precede articular disease in up to 20% of patients and is responsible for 10–20% of deaths.2,3

 Radiographic Pattern of Disease

Once ILD has been identified in a patient, Dr. Highland explained that it is important to understand the radiographic pattern of disease to predict prognosis. Nonspecific interstitial pneumonia combines reticulations and ground glass opacities that tend to be peripheral with an apical to basilar gradient. This is the most common pattern of ILD seen in connective tissue diseases. The presence of ground glass opacities implies inflammatory changes that are potentially reversible. Such findings may also be seen with organizing pneumonia, particularly in patients with rheumatoid arthritis, lupus and idiopathic inflammatory myopathies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In contrast, lymphocytic interstitial pneumonitis, most often seen in patients with Sjögren’s syndrome, and interstitial pneumonia, which can be seen in patients with idiopathic pulmonary fibrosis and rheumatoid arthritis, are fibrotic conditions that are not typically reversible with immunosuppression.

Dr. Highland showed that by combining knowledge of the pattern of ILD seen on high-resolution computed tomography (CT) imaging, the forced vital capacity (FVC) as determined by pulmonary function testing and the histopathologic pattern of disease seen on lung biopsy, patients can be grouped into subsets of CTD-ILD and survival rates can be predicted with reasonable accuracy.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Scleroderma Tagged With: ACR Convergence 2021, connective tissue disease, interstitial lung disease (ILD), nintedanib

You Might Also Like:
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • Tackle Tricky Lung Complications in Connective Tissue Disease
  • Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)